Abstract
Background Understanding the neurobiology behind Fragile X syndrome (FXS) is critical in identifying effective therapeutics and improving care for affected individuals.
Electroencephalography (EEG) provides an opportunity to investigate the biological foundations of this disorder. We aimed to characterize the visual evoked potential (VEP) in young children with FXS, and to understand how measures of the VEP are associated with verbal and nonverbal development within FXS.
Methods VEPs were collected in children between 2-7 years old with FXS (n = 9) as well as corresponding age-(n = 10) and cognitive-matched (n = 9) typically developing children. Additionally, the Mullen Scales of Early Learning and Preschool Language Scales were administered to collect measures of verbal and nonverbal development. Differences in component amplitudes and latencies of the VEP were assessed using ANCOVAs, and associations of VEP measures and verbal and nonverbal development were evaluated using linear regression with age as a covariate.
Results No differences between groups were observed in N1, P1, or N2 VEP components. However, a consistent and prominent P2 component (latency = 177ms ± 13.7), was observed in children with FXS. The P2 amplitude was significantly increased in FXS children compared to the cognitive-matched group (p = 0.004). For children with FXS, the amplitude of several VEP components were associated with verbal and nonverbal development; larger N1 amplitude and smaller P1 and P2 amplitudes were all associated with better receptive language (all p<0.05) and larger N1 amplitude was also associated with better fine motor skills (p<0.05).
Conclusions The observed increase in P2 amplitude and its negative association with language development within the FXS group supports the P2 component as a potential biomarker for FXS as a disorder, as well as a pathophysiological marker of verbal impairment that could be used in clinical trials.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Support for this work was provided by: FRAXA Research Foundation, Autism Science Foundation, The Pierce Family Fragile X Foundation, Thrasher Research Fund, Society for Developmental Behavioral Pediatrics, Harvard Catalyst Medical Research Investigator Training Award, the National Fragile X Foundation, and the National Institutes of Health (1T32MH112510, 1K23DC017983-01A1, R01DC010290).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Boston Children's Hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding authors on reasonable request.
List of Abbreviations
- ADHD
- Attention Deficit Hyperactivity Disorder
- ADOS
- Autism Diagnostic Observation Schedule
- ANCOVA
- Analysis of Covariance
- ANOVA
- Analysis of Variance
- ASD
- Autism Spectrum Disorder
- EEG
- Electroencephalogram
- ERP
- Event Related Potential
- FDR
- False Discovery Rate
- FXS
- Fragile X Syndrome
- FMRP
- Fragile X Messenger Ribonucleoprotein 1
- GABA
- Gamma-Aminobutyric Acid
- HAPPE+ER
- Harvard Automated Processing Pipeline for Electroencephalography plus Event-Related Software
- MSEL
- Mullen Scales of Early Learning
- NVDQ
- Nonverbal Developmental Quotient
- PLS
- Preschool Language Scale
- TSC
- Tuberous Sclerosis Complex
- VEP
- Visual Evoked Potential
